PURPOSE: The role of dobutamine during septic shock resuscitation is still controversial since most clinical studies have been uncontrolled and no physiological study has unequivocally demonstrated a beneficial effect on tissue perfusion. Our objective was to determine the potential benefits of dobutamine on hemodynamic, metabolic, peripheral, hepatosplanchnic and microcirculatory perfusion parameters during early septic shock resuscitation. METHODS: We designed a randomized, controlled, double-blind, crossover study comparing the effects of 2.5-h infusion of dobutamine (5 mcg/kg/min fixed-dose) or placebo in 20 septic shock patients with cardiac index ≥2.5 l/min/m(2) and hyperlactatemia. Primary outcome was sublingual perfused microvascular density. RESULTS: Despite an increasing cardiac index, heart rate and left ventricular ejection fraction, dobutamine had no effect on sublingual perfused vessel density [9.0 (7.9-10.1) vs. 9.1 n/mm (7.9-9.9); p = 0.24] or microvascular flow index [2.1 (1.8-2.5) vs. 2.1 (1.9-2.5); p = 0.73] compared to placebo. No differences between dobutamine and placebo were found for the lactate levels, mixed venous-arterial pCO2 gradient, thenar muscle oxygen saturation, capillary refill time or gastric-to-arterial pCO2 gradient. The indocyanine green plasma disappearance rate [14.4 (9.5-25.6) vs. 18.8 %/min (11.7-24.6); p = 0.03] and the recovery slope of thenar muscle oxygen saturation after a vascular occlusion test [2.1 (1.1-3.1) vs. 2.5 %/s (1.2-3.4); p = 0.01] were worse with dobutamine compared to placebo. CONCLUSIONS:Dobutamine failed to improve sublingual microcirculatory, metabolic, hepatosplanchnic or peripheral perfusion parameters despite inducing a significant increase in systemic hemodynamic variables in septic shock patients without low cardiac output but with persistent hypoperfusion.
RCT Entities:
PURPOSE: The role of dobutamine during septic shock resuscitation is still controversial since most clinical studies have been uncontrolled and no physiological study has unequivocally demonstrated a beneficial effect on tissue perfusion. Our objective was to determine the potential benefits of dobutamine on hemodynamic, metabolic, peripheral, hepatosplanchnic and microcirculatory perfusion parameters during early septic shock resuscitation. METHODS: We designed a randomized, controlled, double-blind, crossover study comparing the effects of 2.5-h infusion of dobutamine (5 mcg/kg/min fixed-dose) or placebo in 20 septic shockpatients with cardiac index ≥2.5 l/min/m(2) and hyperlactatemia. Primary outcome was sublingual perfused microvascular density. RESULTS: Despite an increasing cardiac index, heart rate and left ventricular ejection fraction, dobutamine had no effect on sublingual perfused vessel density [9.0 (7.9-10.1) vs. 9.1 n/mm (7.9-9.9); p = 0.24] or microvascular flow index [2.1 (1.8-2.5) vs. 2.1 (1.9-2.5); p = 0.73] compared to placebo. No differences between dobutamine and placebo were found for the lactate levels, mixed venous-arterial pCO2 gradient, thenar muscle oxygen saturation, capillary refill time or gastric-to-arterial pCO2 gradient. The indocyanine green plasma disappearance rate [14.4 (9.5-25.6) vs. 18.8 %/min (11.7-24.6); p = 0.03] and the recovery slope of thenar muscle oxygen saturation after a vascular occlusion test [2.1 (1.1-3.1) vs. 2.5 %/s (1.2-3.4); p = 0.01] were worse with dobutamine compared to placebo. CONCLUSIONS:Dobutamine failed to improve sublingual microcirculatory, metabolic, hepatosplanchnic or peripheral perfusion parameters despite inducing a significant increase in systemic hemodynamic variables in septic shockpatients without low cardiac output but with persistent hypoperfusion.
Authors: L M Joly; M Monchi; A Cariou; J D Chiche; F Bellenfant; F Brunet; J F Dhainaut Journal: Am J Respir Crit Care Med Date: 1999-12 Impact factor: 21.405
Authors: Glenn Hernandez; Cesar Pedreros; Enrique Veas; Alejandro Bruhn; Carlos Romero; Maximiliano Rovegno; Rodolfo Neira; Sebastian Bravo; Ricardo Castro; Eduardo Kattan; Can Ince Journal: J Crit Care Date: 2011-07-27 Impact factor: 3.425
Authors: Daniel De Backer; Jacques Creteur; Marc-Jacques Dubois; Yasser Sakr; Marc Koch; Colin Verdant; Jean-Louis Vincent Journal: Crit Care Med Date: 2006-02 Impact factor: 7.598
Authors: Wilbert T Jellema; A B Johan Groeneveld; Karel H Wesseling; Lambertus G Thijs; Nico Westerhof; Johannes J van Lieshout Journal: Crit Care Med Date: 2006-09 Impact factor: 7.598
Authors: R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno Journal: Intensive Care Med Date: 2013-01-30 Impact factor: 17.440
Authors: Andrea Morelli; Abele Donati; Christian Ertmer; Sebastian Rehberg; Matthias Lange; Alessandra Orecchioni; Valeria Cecchini; Giovanni Landoni; Paolo Pelaia; Paolo Pietropaoli; Hugo Van Aken; Jean-Louis Teboul; Can Ince; Martin Westphal Journal: Crit Care Date: 2010-12-23 Impact factor: 9.097
Authors: Daniel De Backer; Steven Hollenberg; Christiaan Boerma; Peter Goedhart; Gustavo Büchele; Gustavo Ospina-Tascon; Iwan Dobbe; Can Ince Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Daniel De Backer; Maurizio Cecconi; Jeffrey Lipman; Flavia Machado; Sheila Nainan Myatra; Marlies Ostermann; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Keith R Walley Journal: Intensive Care Med Date: 2019-02-11 Impact factor: 17.440
Authors: Rémi Coudroy; Angéline Jamet; Jean-Pierre Frat; Anne Veinstein; Delphine Chatellier; Véronique Goudet; Severin Cabasson; Arnaud W Thille; René Robert Journal: Intensive Care Med Date: 2014-12-17 Impact factor: 17.440
Authors: Djillali Annane; Lamia Ouanes-Besbes; Daniel de Backer; Bin DU; Anthony C Gordon; Glenn Hernández; Keith M Olsen; Tiffany M Osborn; Sandra Peake; James A Russell; Sergio Zanotti Cavazzoni Journal: Intensive Care Med Date: 2018-06-04 Impact factor: 17.440